Cancer radioimmunotherapy: Development of an effective approach. Progress report, 1985

摘要

The objective of this program is the development of effective approaches for delivering radiation therapy to patients with cancer using radiopharmaceuticals produced from monoclonal antibodies. One major achievement of this program has been the development of a new, Cu-67 chelator (Teta). This chelator firmly holds copper even in the presence of competitive serum proteins. Copper has proven to be labile with other chelators. Also, a single photon emission tomographic camera was purchased with University and philanthropic funds specifically for this program. This allows full-time developmental work on quantitative imaging approaches and in vivo kinetics of our various radiopharmaceutical antibody products. The pharmakinetics of I-123 antibody and antibody fragments have been obtained in patients utilizing quantitative imaging and have demonstrated significant differences as well as the need for long- term studies with I-131 and Cu-67.